Trial · NCT00113204
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
NCT00113204, Phase 1, Completed, Infinity Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma. Trials, record NCT00113204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00113204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
- NCT number
- NCT00113204
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Conditions
- Multiple Myeloma
- Interventions
- IPI-504
- First posted
- 2005-06-07
- Last updated
- 2008-05-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To determine the safety and maximum tolerated dose of IPI-504 | Following 1 cycle of treatment | |
| Primary | Recommend a dose for subsequent studies of IPI-504 | Once MTD is reached | |
| Secondary | To examine the pharmacokinetic parameters of IPI-504 | During first dose first cycle of IPI-504 | |
| Secondary | To evaluate the potential anti-tumor activity with standard markers of disease progression | 1 cycle of treatment | |
| Secondary | To examine pharmacodynamic markers of biologic activity of IPI-504 | Cycle 1 of treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00113204
GET https://conductscience.org/api/trials/v1/NCT00113204/registered